NRX Pharmaceuticals (NRXP) Change in Cash (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Change in Cash for 10 consecutive years, with -$1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash fell 126.41% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $1.2 million (down 72.45% YoY), while the FY2025 annual figure was $6.4 million, up 301.59% from the prior year.
• Change in Cash eased to -$1.1 million in Q1 2026 per NRXP's latest filing, from $613000.0 in the prior quarter.
• Across five years, Change in Cash topped out at $12.6 million in Q1 2022 and bottomed at -$15.7 million in Q2 2022.
• Historically, Change in Cash has averaged -$1.2 million across 5 years, with a median of -$1.1 million in 2026.
• Annual changes were most pronounced in 2022 — Change in Cash plunged 13712.17% — and 2025, when it soared 1796.03%.
• NRX Pharmaceuticals' Change in Cash stood at $1.8 million in 2022, then slumped by 338.61% to -$4.3 million in 2023, then soared by 95.29% to -$203000.0 in 2024, then surged by 401.97% to $613000.0 in 2025, then tumbled by 276.84% to -$1.1 million in 2026.
• Business Quant data shows NRXP's Change in Cash at -$1.1 million in Q1 2026, $613000.0 in Q4 2025, and $4.3 million in Q3 2025.